These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17202412)

  • 1. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY; Parker E; El Nahas M; Haylor JL; Ong AC
    J Am Soc Nephrol; 2007 Feb; 18(2):560-9. PubMed ID: 17202412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
    Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable renal disease progression in autosomal dominant polycystic kidney disease: a role for nitric oxide?
    Devuyst O
    J Nephrol; 2003; 16(3):449-52. PubMed ID: 12832751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1.
    Wang E; Hsieh-Li HM; Chiou YY; Chien YL; Ho HH; Chin HJ; Wang CK; Liang SC; Jiang ST
    J Pathol; 2010 Nov; 222(3):238-48. PubMed ID: 20814903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.
    Happé H; Leonhard WN; van der Wal A; van de Water B; Lantinga-van Leeuwen IS; Breuning MH; de Heer E; Peters DJ
    Hum Mol Genet; 2009 Jul; 18(14):2532-42. PubMed ID: 19401297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Variable progression of autosomal dominant polycystic kidney disease: genetic and molecular counterparts].
    Devuyst O
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S104-8. PubMed ID: 17373208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease.
    Hocher B; Kalk P; Slowinski T; Godes M; Mach A; Herzfeld S; Wiesner D; Arck PC; Neumayer HH; Nafz B
    J Am Soc Nephrol; 2003 Feb; 14(2):367-76. PubMed ID: 12538737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of progression in autosomal dominant polycystic kidney disease.
    Grantham JJ
    Kidney Int Suppl; 1997 Dec; 63():S93-7. PubMed ID: 9407432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis.
    Xu N; Glockner JF; Rossetti S; Babovich-Vuksanovic D; Harris PC; Torres VE
    J Nephrol; 2006; 19(4):529-34. PubMed ID: 17048214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease.
    Gattone VH; Siqueira TM; Powell CR; Trambaugh CM; Lingeman JE; Shalhav AL
    Exp Biol Med (Maywood); 2008 Aug; 233(8):952-7. PubMed ID: 18480417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low NaCl intake elevates renal medullary endothelin-1 and endothelin A (ETA) receptor mRNA but not the sensitivity of renal Na+ excretion to ETA receptor blockade in rats.
    Klinger F; Grimm R; Steinbach A; Tanneberger M; Kunert-Keil C; Rettig R; Grisk O
    Acta Physiol (Oxf); 2008 Mar; 192(3):429-42. PubMed ID: 17892519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic approach in autosomal dominant polycystic kidney disease.
    Pei Y
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1108-14. PubMed ID: 17699332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular characterization of Pkd2(+/LacZ) mice, an animal model for the autosomal dominant polycystic kidney disease type 2 (ADPKD2).
    Stypmann J; Engelen MA; Orwat S; Bilbilis K; Rothenburger M; Eckardt L; Haverkamp W; Horst J; Dworniczak B; Pennekamp P
    Int J Cardiol; 2007 Aug; 120(2):158-66. PubMed ID: 17182135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin in polycystic kidney disease.
    Chang MY; Ong ACM
    Contrib Nephrol; 2011; 172():200-209. PubMed ID: 21894000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease.
    Ong AC; Newby LJ; Dashwood MR
    Nephron Exp Nephrol; 2003; 93(2):e80. PubMed ID: 12629276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.